Epileptic disorders : international epilepsy journal with videotape · 2026
The role of SCN1A mutations in temporal lobe epilepsy: Genetic insights and clinical implications.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Alrabadi Bassel, Matar Hasan, Marouf Mahmoud, Bandak Natalie, Batarseh Suhel F, Badran Zaid, O Hazaimeh Haitham, Yassin Ahmed
Аннотация
PURPOSE: Temporal lobe epilepsy (TLE) is the most common focal epilepsy, yet the genetic mechanisms underlying its development remain incompletely understood. The sodium channel gene SCN1A, known to be involved in several epilepsy syndromes including Dravet syndrome and genetic epilepsy with febrile seizures plus (GEFS+), has recently been investigated for its potential role in TLE. This systematic review aimed to synthesize evidence on the role of SCN1A variants in the pathogenesis, clinical features, and treatment outcomes of TLE.
METHODS: A comprehensive literature search of PubMed, Scopus, Web of Science, and the Cochrane Library was conducted up to September 2024. Twenty-six eligible studies, including clinical, molecular, and preclinical investigations, were analyzed to assess associations between SCN1A mutations or polymorphisms and TLE phenotypes, with particular focus on genetic, electrophysiological, and therapeutic findings.
RESULTS: Clinical studies reported both common polymorphisms (rs3812718, rs7587026) and rare familial variants (M145T, K1270T) in patients with mesial TLE with hippocampal sclerosis (MTLE-HS) and drug resistance. Transcriptomic and electrophysiological analyses of resected hippocampal tissue suggested altered SCN1A expression and possible interneuron dysfunction. Experimental models further indicated that SCN1A dysregulation may influence hippocampal excitability and seizure thresholds, while sodium channel modulators such as carbamazepine were reported to normalize aberrant expression patterns and reduce epileptiform activity.
CONCLUSION: Current evidence suggests that SCN1A may act as a genetic modifier contributing to TLE susceptibility, pharmacoresistance, and clinical heterogeneity in certain contexts. Integration of genetic and molecular data may support improved phenotypic characterization and individualized management in selected patients. However, larger and well-designed studies incorporating multi-omics and longitudinal data are required to clarify the mechanistic and clinical relevance of SCN1A in TLE.
METHODS: A comprehensive literature search of PubMed, Scopus, Web of Science, and the Cochrane Library was conducted up to September 2024. Twenty-six eligible studies, including clinical, molecular, and preclinical investigations, were analyzed to assess associations between SCN1A mutations or polymorphisms and TLE phenotypes, with particular focus on genetic, electrophysiological, and therapeutic findings.
RESULTS: Clinical studies reported both common polymorphisms (rs3812718, rs7587026) and rare familial variants (M145T, K1270T) in patients with mesial TLE with hippocampal sclerosis (MTLE-HS) and drug resistance. Transcriptomic and electrophysiological analyses of resected hippocampal tissue suggested altered SCN1A expression and possible interneuron dysfunction. Experimental models further indicated that SCN1A dysregulation may influence hippocampal excitability and seizure thresholds, while sodium channel modulators such as carbamazepine were reported to normalize aberrant expression patterns and reduce epileptiform activity.
CONCLUSION: Current evidence suggests that SCN1A may act as a genetic modifier contributing to TLE susceptibility, pharmacoresistance, and clinical heterogeneity in certain contexts. Integration of genetic and molecular data may support improved phenotypic characterization and individualized management in selected patients. However, larger and well-designed studies incorporating multi-omics and longitudinal data are required to clarify the mechanistic and clinical relevance of SCN1A in TLE.